First Trimester Abortion
Conditions
Brief summary
This study, a double blinded randomized controlled trial, is being done to compare side effects of commonly used antibiotic regimens prior to same day abortion procedures. In total, 180 pregnant women in their first trimester of pregnancy (5 0/6-13 6/7 weeks gestation) will be randomized to receive one of the three commonly used antibiotics (azithromycin, doxycycline, metronidazole) for same day abortion procedures or placebo prior to their abortion procedure. Approximately, 30-60 mins after study drug administration, the procedure will be performed. A sub-study will be completed on 40 women who consent to endometrial sampling and to have their blood drawn.
Detailed description
Main Study: Women will be randomized to receive single oral doses of azithromycin 500 mg, doxycycline 200 mg, metronidazole 500 mg, or placebo. Computer-generated randomization will be used to assign participants to one of the four treatment arms. Women receiving placebo will receive antibiotic prophylaxis after completion of the study. Both the participants and the investigators will be blinded as to the treatment group. This will be accomplished by placing the study medication inside opaque gelatin capsules. We will randomize participants by assigning them to the next of the sequentially numbered sealed opaque study packets, containing the gelatin capsules with study medication inside. A second envelope will be opened after completion of all study procedure and will only say if the participant received placebo, so that additional antibiotics can be given. Participants will swallow the appropriate medication approximately 30-60 minutes prior to the surgical abortion (15-90 minutes range is acceptable). Study population will be all eligible patients undergoing surgical abortion in the first trimester at Washington Hospital Center and Planned Parenthood Metropolitan Washington. We will assess pain and side effects via written questionnaire at three different time points throughout the day, once at time of consent, before and after the procedure. Patients will be contacted within 1-2 weeks for follow-up and again pain and side effects will be assessed, as well. Sub-study: Forty (n=40) women will be recruited to undergo immediate post-procedure endometrial sampling. Sub-study patients will have a blood sample collected via venipuncture before leaving the procedure room, as well. No testing will be performed for participants receiving placebo. The primary objective is to determine if the side effects associated with individual medications are more similar to placebo than the others. The sub-study aims to explore our ability to identify bacteria within the uterine cavity. The objective is to assess the feasibility of identifying bacteria within the uterus after abortion.
Interventions
500 mg
200 mg
500 mg
Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
Sponsors
Study design
Eligibility
Inclusion criteria
* Women in good general health. * English speaking. * Age 18 or over. * Seeking non-urgent surgical termination of pregnancy. * Gestational age of 5 0/7 to 13 6/7 weeks, confirmed by sonogram.
Exclusion criteria
* Less than 18 years of age. * Early pregnancy failure or fetal demise. * Poor general health that would prevent one from tolerating the medication or surgical procedure. * Intolerance, allergy, or contraindication to any of the study medications. * Inability to tolerate oral intake due to current nausea or vomiting. * Diagnosis of hyperemesis gravidarum with current pregnancy. * Need of an urgent surgical abortion. * Gestational age outside of 5-13 6/7 weeks by sonogram.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Emesis Severity | 1 Day | Emesis severity assessment collected at different time points (None, Mild, Moderate, Severe) |
| Nausea Scale | 1 Day | Nausea symptom was collected at different time points via surveys (None, Mild, Moderate, Severe) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Scale | Day 1 | Pain symptoms will be collected at different time points via surveys (None, Mild, Moderate, Severe) |
| Serum Antibiotic Levels | 3 hours | Serum antibiotic levels drawn at time of endometrial sampling in subset of patients |
| Endometrial Growth | 3 Days | Endometrial Growth on non-selective, Staph Selective, Strep Selective, and Gram negative selective Agar |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Azithromycin 500 mg of Azithromycin
Azithromycin: 500 mg | 46 |
| Doxycycline 200 mg of Doxycycline
Doxycycline: 200 mg | 42 |
| Metronidazole 500 mg of Metronidazole
Metronidazole: 500 mg | 41 |
| Placebo Inactive Ingredient
Placebo: Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration. | 45 |
| Total | 174 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Changed Mind About Procedure | 0 | 0 | 1 | 0 |
| Overall Study | Did not complete Procedure | 0 | 1 | 0 | 0 |
| Overall Study | Protocol Violation | 0 | 1 | 0 | 1 |
| Overall Study | Unable to swallow medication | 0 | 1 | 1 | 1 |
Baseline characteristics
| Characteristic | Total | Placebo | Metronidazole | Doxycycline | Azithromycin |
|---|---|---|---|---|---|
| Age, Continuous | 26.6 years STANDARD_DEVIATION 5.9 | 28.6 years STANDARD_DEVIATION 6.1 | 26.5 years STANDARD_DEVIATION 5.5 | 26.2 years STANDARD_DEVIATION 6.4 | 25.1 years STANDARD_DEVIATION 5 |
| BMI | 28.3 kg/m^2 STANDARD_DEVIATION 7.3 | 29.0 kg/m^2 STANDARD_DEVIATION 7 | 29.5 kg/m^2 STANDARD_DEVIATION 8.5 | 27.0 kg/m^2 STANDARD_DEVIATION 7.3 | 27.8 kg/m^2 STANDARD_DEVIATION 6.2 |
| Education College Grad | 28 Participants | 10 Participants | 4 Participants | 5 Participants | 9 Participants |
| Education Graduate School | 8 Participants | 2 Participants | 1 Participants | 3 Participants | 2 Participants |
| Education HS Grad or Equivalent | 62 Participants | 16 Participants | 13 Participants | 16 Participants | 17 Participants |
| Education Less than High School | 7 Participants | 0 Participants | 3 Participants | 0 Participants | 4 Participants |
| Education Some College | 69 Participants | 17 Participants | 20 Participants | 18 Participants | 14 Participants |
| Gestational age | 64.3 days STANDARD_DEVIATION 15.7 | 67.5 days STANDARD_DEVIATION 15.8 | 65 days STANDARD_DEVIATION 12.2 | 63.9 days STANDARD_DEVIATION 17.1 | 60.9 days STANDARD_DEVIATION 16.8 |
| Marital Status Cohabitating | 14 Participants | 4 Participants | 3 Participants | 1 Participants | 6 Participants |
| Marital Status Divorced | 5 Participants | 3 Participants | 1 Participants | 1 Participants | 0 Participants |
| Marital Status Married | 21 Participants | 5 Participants | 3 Participants | 9 Participants | 4 Participants |
| Marital Status Separated | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Marital Status Single | 132 Participants | 31 Participants | 34 Participants | 31 Participants | 36 Participants |
| Parous Nulliparous | 65 Participants | 17 Participants | 10 Participants | 17 Participants | 21 Participants |
| Parous Parous | 109 Participants | 28 Participants | 31 Participants | 25 Participants | 25 Participants |
| Prior Abortion No | 72 Participants | 11 Participants | 15 Participants | 21 Participants | 25 Participants |
| Prior Abortion Yes | 102 Participants | 34 Participants | 26 Participants | 21 Participants | 21 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 2 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 121 Participants | 34 Participants | 27 Participants | 31 Participants | 29 Participants |
| Race (NIH/OMB) More than one race | 20 Participants | 5 Participants | 4 Participants | 4 Participants | 7 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 24 Participants | 4 Participants | 7 Participants | 6 Participants | 7 Participants |
| Sex: Female, Male Female | 174 Participants | 45 Participants | 41 Participants | 42 Participants | 46 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Work Status Full Time Student | 17 participants | 4 participants | 4 participants | 5 participants | 4 participants |
| Work Status Full Time Work | 78 participants | 23 participants | 16 participants | 19 participants | 20 participants |
| Work Status Homemaker | 3 participants | 1 participants | 1 participants | 1 participants | 0 participants |
| Work Status Other | 1 participants | 1 participants | 0 participants | 0 participants | 0 participants |
| Work Status Part Time Work | 33 participants | 10 participants | 9 participants | 6 participants | 8 participants |
| Work Status Unemployed | 44 participants | 6 participants | 11 participants | 13 participants | 14 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 41 | 0 / 46 | 0 / 42 | 0 / 45 |
| other Total, other adverse events | 0 / 41 | 0 / 46 | 0 / 42 | 0 / 45 |
| serious Total, serious adverse events | 1 / 41 | 0 / 46 | 0 / 42 | 0 / 45 |
Outcome results
Emesis Severity
Emesis severity assessment collected at different time points (None, Mild, Moderate, Severe)
Time frame: 1 Day
Population: 4 Subjects failed to complete the entire post-procedure survey: 1 Azithromycin group, 2 in Metronidazole group, 1 in Placebo group
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Azithromycin | Emesis Severity | Before Procedure | Mild | 1 Participants |
| Azithromycin | Emesis Severity | Baseline | Moderate | 6 Participants |
| Azithromycin | Emesis Severity | Baseline | Severe | 8 Participants |
| Azithromycin | Emesis Severity | Before Procedure | None | 43 Participants |
| Azithromycin | Emesis Severity | After Procedure | Mild | 2 Participants |
| Azithromycin | Emesis Severity | Baseline | None | 20 Participants |
| Azithromycin | Emesis Severity | After Procedure | Severe | 0 Participants |
| Azithromycin | Emesis Severity | After Procedure | None | 42 Participants |
| Azithromycin | Emesis Severity | Before Procedure | Severe | 0 Participants |
| Azithromycin | Emesis Severity | Baseline | Mild | 12 Participants |
| Azithromycin | Emesis Severity | After Procedure | Moderate | 1 Participants |
| Azithromycin | Emesis Severity | Before Procedure | Moderate | 2 Participants |
| Doxycycline | Emesis Severity | Baseline | Moderate | 6 Participants |
| Doxycycline | Emesis Severity | Baseline | None | 24 Participants |
| Doxycycline | Emesis Severity | Baseline | Mild | 8 Participants |
| Doxycycline | Emesis Severity | Baseline | Severe | 4 Participants |
| Doxycycline | Emesis Severity | Before Procedure | None | 42 Participants |
| Doxycycline | Emesis Severity | Before Procedure | Mild | 0 Participants |
| Doxycycline | Emesis Severity | Before Procedure | Moderate | 0 Participants |
| Doxycycline | Emesis Severity | Before Procedure | Severe | 0 Participants |
| Doxycycline | Emesis Severity | After Procedure | None | 35 Participants |
| Doxycycline | Emesis Severity | After Procedure | Mild | 1 Participants |
| Doxycycline | Emesis Severity | After Procedure | Moderate | 5 Participants |
| Doxycycline | Emesis Severity | After Procedure | Severe | 1 Participants |
| Metronidazole | Emesis Severity | Baseline | Mild | 16 Participants |
| Metronidazole | Emesis Severity | After Procedure | Moderate | 0 Participants |
| Metronidazole | Emesis Severity | Before Procedure | Moderate | 0 Participants |
| Metronidazole | Emesis Severity | Before Procedure | Severe | 0 Participants |
| Metronidazole | Emesis Severity | Baseline | None | 13 Participants |
| Metronidazole | Emesis Severity | Baseline | Moderate | 11 Participants |
| Metronidazole | Emesis Severity | After Procedure | None | 39 Participants |
| Metronidazole | Emesis Severity | Before Procedure | Mild | 0 Participants |
| Metronidazole | Emesis Severity | After Procedure | Mild | 0 Participants |
| Metronidazole | Emesis Severity | Baseline | Severe | 1 Participants |
| Metronidazole | Emesis Severity | Before Procedure | None | 41 Participants |
| Metronidazole | Emesis Severity | After Procedure | Severe | 0 Participants |
| Placebo | Emesis Severity | Before Procedure | Mild | 1 Participants |
| Placebo | Emesis Severity | After Procedure | Severe | 0 Participants |
| Placebo | Emesis Severity | Before Procedure | None | 44 Participants |
| Placebo | Emesis Severity | Before Procedure | Moderate | 0 Participants |
| Placebo | Emesis Severity | Baseline | None | 17 Participants |
| Placebo | Emesis Severity | After Procedure | Moderate | 0 Participants |
| Placebo | Emesis Severity | After Procedure | Mild | 0 Participants |
| Placebo | Emesis Severity | Before Procedure | Severe | 0 Participants |
| Placebo | Emesis Severity | Baseline | Severe | 5 Participants |
| Placebo | Emesis Severity | Baseline | Mild | 15 Participants |
| Placebo | Emesis Severity | Baseline | Moderate | 8 Participants |
| Placebo | Emesis Severity | After Procedure | None | 44 Participants |
Nausea Scale
Nausea symptom was collected at different time points via surveys (None, Mild, Moderate, Severe)
Time frame: 1 Day
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Azithromycin | Nausea Scale | Baseline | None | 8 Participants |
| Azithromycin | Nausea Scale | Before Procedure | Mild | 8 Participants |
| Azithromycin | Nausea Scale | Before Procedure | None | 34 Participants |
| Azithromycin | Nausea Scale | Baseline | Severe | 7 Participants |
| Azithromycin | Nausea Scale | After Procedure | Severe | 0 Participants |
| Azithromycin | Nausea Scale | After Procedure | Mild | 7 Participants |
| Azithromycin | Nausea Scale | After Procedure | None | 35 Participants |
| Azithromycin | Nausea Scale | Baseline | Mild | 18 Participants |
| Azithromycin | Nausea Scale | After Procedure | Moderate | 4 Participants |
| Azithromycin | Nausea Scale | Before Procedure | Severe | 2 Participants |
| Azithromycin | Nausea Scale | Before Procedure | Moderate | 2 Participants |
| Azithromycin | Nausea Scale | Baseline | Moderate | 13 Participants |
| Doxycycline | Nausea Scale | After Procedure | Mild | 5 Participants |
| Doxycycline | Nausea Scale | Baseline | None | 9 Participants |
| Doxycycline | Nausea Scale | Baseline | Mild | 15 Participants |
| Doxycycline | Nausea Scale | Baseline | Moderate | 11 Participants |
| Doxycycline | Nausea Scale | Baseline | Severe | 7 Participants |
| Doxycycline | Nausea Scale | Before Procedure | None | 36 Participants |
| Doxycycline | Nausea Scale | Before Procedure | Mild | 4 Participants |
| Doxycycline | Nausea Scale | Before Procedure | Moderate | 2 Participants |
| Doxycycline | Nausea Scale | Before Procedure | Severe | 0 Participants |
| Doxycycline | Nausea Scale | After Procedure | None | 28 Participants |
| Doxycycline | Nausea Scale | After Procedure | Moderate | 6 Participants |
| Doxycycline | Nausea Scale | After Procedure | Severe | 3 Participants |
| Metronidazole | Nausea Scale | After Procedure | Moderate | 1 Participants |
| Metronidazole | Nausea Scale | Before Procedure | Mild | 5 Participants |
| Metronidazole | Nausea Scale | Before Procedure | Moderate | 0 Participants |
| Metronidazole | Nausea Scale | Baseline | Mild | 10 Participants |
| Metronidazole | Nausea Scale | After Procedure | Mild | 6 Participants |
| Metronidazole | Nausea Scale | Before Procedure | Severe | 0 Participants |
| Metronidazole | Nausea Scale | After Procedure | None | 34 Participants |
| Metronidazole | Nausea Scale | Baseline | None | 6 Participants |
| Metronidazole | Nausea Scale | Baseline | Severe | 5 Participants |
| Metronidazole | Nausea Scale | After Procedure | Severe | 0 Participants |
| Metronidazole | Nausea Scale | Before Procedure | None | 36 Participants |
| Metronidazole | Nausea Scale | Baseline | Moderate | 20 Participants |
| Placebo | Nausea Scale | After Procedure | Severe | 0 Participants |
| Placebo | Nausea Scale | Baseline | Severe | 9 Participants |
| Placebo | Nausea Scale | Before Procedure | Mild | 5 Participants |
| Placebo | Nausea Scale | Baseline | Mild | 14 Participants |
| Placebo | Nausea Scale | After Procedure | Moderate | 0 Participants |
| Placebo | Nausea Scale | After Procedure | None | 37 Participants |
| Placebo | Nausea Scale | Before Procedure | Moderate | 0 Participants |
| Placebo | Nausea Scale | Baseline | Moderate | 16 Participants |
| Placebo | Nausea Scale | After Procedure | Mild | 8 Participants |
| Placebo | Nausea Scale | Before Procedure | None | 39 Participants |
| Placebo | Nausea Scale | Before Procedure | Severe | 1 Participants |
| Placebo | Nausea Scale | Baseline | None | 6 Participants |
Endometrial Growth
Endometrial Growth on non-selective, Staph Selective, Strep Selective, and Gram negative selective Agar
Time frame: 3 Days
Population: Subset of patients with endometrial swab cultured
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Azithromycin | Endometrial Growth | Streptococcus Agar (Strep selective) | 1 Participants |
| Azithromycin | Endometrial Growth | Trypic Soy Non-Selective Agar | 3 Participants |
| Azithromycin | Endometrial Growth | MacConkey Agar (gram neg selective) | 0 Participants |
| Azithromycin | Endometrial Growth | Mannitol Salt Agar (Staph selective) | 1 Participants |
| Azithromycin | Endometrial Growth | No Growth | 4 Participants |
| Doxycycline | Endometrial Growth | Mannitol Salt Agar (Staph selective) | 2 Participants |
| Doxycycline | Endometrial Growth | Streptococcus Agar (Strep selective) | 1 Participants |
| Doxycycline | Endometrial Growth | MacConkey Agar (gram neg selective) | 0 Participants |
| Doxycycline | Endometrial Growth | Trypic Soy Non-Selective Agar | 4 Participants |
| Doxycycline | Endometrial Growth | No Growth | 7 Participants |
| Metronidazole | Endometrial Growth | Mannitol Salt Agar (Staph selective) | 0 Participants |
| Metronidazole | Endometrial Growth | No Growth | 8 Participants |
| Metronidazole | Endometrial Growth | Trypic Soy Non-Selective Agar | 3 Participants |
| Metronidazole | Endometrial Growth | Streptococcus Agar (Strep selective) | 1 Participants |
| Metronidazole | Endometrial Growth | MacConkey Agar (gram neg selective) | 0 Participants |
| Placebo | Endometrial Growth | Streptococcus Agar (Strep selective) | 3 Participants |
| Placebo | Endometrial Growth | Trypic Soy Non-Selective Agar | 2 Participants |
| Placebo | Endometrial Growth | No Growth | 1 Participants |
| Placebo | Endometrial Growth | Mannitol Salt Agar (Staph selective) | 1 Participants |
| Placebo | Endometrial Growth | MacConkey Agar (gram neg selective) | 0 Participants |
Pain Scale
Pain symptoms will be collected at different time points via surveys (None, Mild, Moderate, Severe)
Time frame: Day 1
Population: 4 patients had incomplete post-procedure surveys: 1 in Azithromycin group, 2 in Metronidazole group, 1 in Placebo group
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Azithromycin | Pain Scale | After Procedure | Mild | 18 Participants |
| Azithromycin | Pain Scale | After Procedure | Severe | 3 Participants |
| Azithromycin | Pain Scale | Before Procedure | Severe | 1 Participants |
| Azithromycin | Pain Scale | Baseline Pain | None | 20 Participants |
| Azithromycin | Pain Scale | After Procedure | None | 18 Participants |
| Azithromycin | Pain Scale | Baseline Pain | Moderate | 6 Participants |
| Azithromycin | Pain Scale | Baseline Pain | Severe | 2 Participants |
| Azithromycin | Pain Scale | Baseline Pain | Mild | 18 Participants |
| Azithromycin | Pain Scale | After Procedure | Moderate | 6 Participants |
| Azithromycin | Pain Scale | Before Procedure | None | 35 Participants |
| Azithromycin | Pain Scale | Before Procedure | Mild | 9 Participants |
| Azithromycin | Pain Scale | Before Procedure | Moderate | 1 Participants |
| Doxycycline | Pain Scale | Baseline Pain | Mild | 14 Participants |
| Doxycycline | Pain Scale | Before Procedure | Moderate | 0 Participants |
| Doxycycline | Pain Scale | Baseline Pain | Severe | 3 Participants |
| Doxycycline | Pain Scale | After Procedure | None | 16 Participants |
| Doxycycline | Pain Scale | After Procedure | Mild | 17 Participants |
| Doxycycline | Pain Scale | Before Procedure | Severe | 0 Participants |
| Doxycycline | Pain Scale | Baseline Pain | None | 17 Participants |
| Doxycycline | Pain Scale | Before Procedure | Mild | 4 Participants |
| Doxycycline | Pain Scale | Before Procedure | None | 38 Participants |
| Doxycycline | Pain Scale | Baseline Pain | Moderate | 8 Participants |
| Doxycycline | Pain Scale | After Procedure | Severe | 2 Participants |
| Doxycycline | Pain Scale | After Procedure | Moderate | 7 Participants |
| Metronidazole | Pain Scale | Before Procedure | Severe | 0 Participants |
| Metronidazole | Pain Scale | Baseline Pain | None | 16 Participants |
| Metronidazole | Pain Scale | Baseline Pain | Mild | 16 Participants |
| Metronidazole | Pain Scale | Baseline Pain | Moderate | 6 Participants |
| Metronidazole | Pain Scale | Baseline Pain | Severe | 3 Participants |
| Metronidazole | Pain Scale | Before Procedure | None | 35 Participants |
| Metronidazole | Pain Scale | Before Procedure | Mild | 6 Participants |
| Metronidazole | Pain Scale | Before Procedure | Moderate | 0 Participants |
| Metronidazole | Pain Scale | After Procedure | None | 9 Participants |
| Metronidazole | Pain Scale | After Procedure | Mild | 17 Participants |
| Metronidazole | Pain Scale | After Procedure | Moderate | 12 Participants |
| Metronidazole | Pain Scale | After Procedure | Severe | 1 Participants |
| Placebo | Pain Scale | Before Procedure | Mild | 5 Participants |
| Placebo | Pain Scale | Before Procedure | None | 39 Participants |
| Placebo | Pain Scale | Baseline Pain | None | 13 Participants |
| Placebo | Pain Scale | After Procedure | Mild | 16 Participants |
| Placebo | Pain Scale | Baseline Pain | Severe | 3 Participants |
| Placebo | Pain Scale | Baseline Pain | Moderate | 11 Participants |
| Placebo | Pain Scale | After Procedure | Severe | 2 Participants |
| Placebo | Pain Scale | After Procedure | Moderate | 11 Participants |
| Placebo | Pain Scale | Before Procedure | Severe | 0 Participants |
| Placebo | Pain Scale | Before Procedure | Moderate | 1 Participants |
| Placebo | Pain Scale | Baseline Pain | Mild | 18 Participants |
| Placebo | Pain Scale | After Procedure | None | 15 Participants |
Serum Antibiotic Levels
Serum antibiotic levels drawn at time of endometrial sampling in subset of patients
Time frame: 3 hours
Population: Subset of patients who had serum antibiotic levels drawn
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Azithromycin | Serum Antibiotic Levels | 0.41 mcg/mL | Standard Deviation 0.22 |
| Doxycycline | Serum Antibiotic Levels | 1.1 mcg/mL | Standard Deviation 0.8 |
| Metronidazole | Serum Antibiotic Levels | 8.2 mcg/mL | Standard Deviation 3.8 |